Press Releases

Date Title
August 24, 2021 Progenity Announces Closing of $40 Million Underwritten Public Offering
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000
August 19, 2021 Progenity Announces Pricing of $40 Million Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the pricing of its previously announced underwritten public offering of 40,000,000 shares of its common stock and warrants to purchase up to 40,000,000
August 19, 2021 Progenity Announces Proposed Underwritten Public Offering of Common Stock and Warrants
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock
August 12, 2021 Progenity Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Announced successful completion of the validation study PRO-104 for the Preecludia™  rule out test for preeclampsia and achievement of the primary endpoint of the study protocol Recently achieved promising results with the prototype autonomous Oral Biotherapeutics Delivery System in a single oral
August 5, 2021 Progenity to Report Second Quarter 2021 Financial Results and Provide Corporate Update
SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report second quarter 2021 financial results on Thursday, August 12, 2021 after the close of financial markets.
July 29, 2021 Progenity Announces Successful Completion of Clinical Validation Study and Achievement of the Primary Endpoint for its Preeclampsia Rule-Out Test
The company’s Preecludia™ test performed strongly in a broad, intended-use population SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today successful completion of the validation study for its Preecludia™ rule-out test for
June 30, 2021 Progenity Announces Appointment of Surbhi Sarna to its Board of Directors
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced the appointment of Surbhi Sarna to its board of directors effective July 1, 2021. Ms. Surbhi’s medical device experience and her focus on development of strategic partnerships
June 17, 2021 Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board. The advisory board includes respected researchers and clinicians who are thought leaders in the
June 15, 2021 Progenity to Participate in the Raymond James 2021 Human Health Innovation Conference
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that Harry Stylli, PhD, CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Raymond James 2021 Human Health
June 10, 2021 Progenity Announces $40 Million Private Placement
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities purchase agreement with two leading healthcare-focused investment funds for the sale of units consisting
Displaying 21 - 30 of 103